Balyasny Asset Management’s Immunovant IMVT Stock Holding History

Balyasny Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-350,000	Closed	-$13.4M	–	2679
2023 Q3	$13.4M	Buy	+350,000	New	+$7.91M	0.03%	726

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Balyasny Asset Management's IMVT Position: Q4 2025 in Review

Balyasny Asset Management sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 448,051 shares — an estimated $7.22M sold.

Balyasny Asset Management first reported a position in IMVT in Q4 2020 and held it in 8 quarters. The position peaked at $7.22M in Q3 2025. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

Balyasny Asset Management reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
Balyasny Asset Management sold 448,051 Immunovant shares in Q4 2025, an estimated $7.22M.
Balyasny Asset Management first reported a position in Immunovant in Q4 2020 and held it in 8 quarters.
Balyasny Asset Management's Immunovant position peaked at $7.22M in Q3 2025.
196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.